ImmunityBio, Inc.
IBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, ImmunityBio, Inc. (IBRX) is listed under Biotechnology. With a market capitalization of $8.04B, it sits in mid-cap territory. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Market Cap
$8.04B
Beta
0.08
P/E (TTM)
—
P/E (Fwd)
128.00
EPS (TTM)
$-0.88
EPS (Fwd)
$0.06
ROE
—
ROA
-34.4%
Cash
$380.9M
Total Debt
$1.12B
Free CF
-$193.7M
52W Change
179.3%
Annual Financials
Cash vs Debt
On the balance sheet, IBRX has $380.9M in cash with $1.12B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$193.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $240K (2022) to $113.3M (2025), reflecting a 47103% increase over the period.
The relatively low beta of 0.08 suggests IBRX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IBRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.